百济神州(06160.HK)与Royalty Pharma Investments2023 ICAV签订一份特许权使用费购买协议

Group 1 - The core point of the article is that BeiGene (06160.HK) has entered into a royalty purchase agreement with Royalty Pharma Investments 2023 ICAV, involving an upfront payment of $885 million and rights to royalties from the sales of the monoclonal antibody Imdelltra outside of China [1][2]. Group 2 - Under the royalty purchase agreement, Royalty Pharma will pay an upfront fee of $885 million at closing and will acquire most rights to receive a tiered mid-single-digit percentage royalty on the net income from Imdelltra products sold outside of China [2]. - The agreement allows the seller to sell additional royalty rights to Royalty Pharma, potentially earning up to $65 million based on the value of the additional royalties [2]. - The company has assessed the royalty purchase agreement and expects the upfront payment to constitute a significant direct financial obligation under U.S. GAAP at the time of closing [3].